In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on PainReform (PRFX – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $0.83.
According to TipRanks, Rahman is an analyst with an average return of -25.8% and a 22.22% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, 9 Meters Biopharma, and Virpax Pharmaceuticals.
PainReform has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See the top stocks recommended by analysts >>
PRFX market cap is currently $8.66M and has a P/E ratio of -1.23.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company’s product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Read More on PRFX:
- Siebert Williams Shank & Co Remains a Buy on Laredo Petroleum (LPI)
- Deutsche Bank Sticks to Its Hold Rating for BHP Group Ltd (BHPLF)
- Matthews International Acquires OLBRICH GmbH and R+S Automotive GmbH, Extends Engineering Capabilities for Energy
- Clubhouse Media Group, Inc. Reports Second Quarter 2022 Net Revenue of $1.9 Million, a 104% Increase from Same Period in 2021
- Pure Extracts Delivers Its Largest Shipments to Launch its Newest Vape Product
